-

Aerin Medical Appoints Lucas Buchanan as Independent Board Director

MedTech veteran brings deep financial, strategic and commercial expertise

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aerin Medical Inc., a leader in minimally invasive solutions for chronic nasal conditions, today announced the appointment of Lucas Buchanan to its Board of Directors. Mr. Buchanan will serve as an independent director, bringing important expertise and strategic perspective to guide Aerin’s significant value creation.

Mr. Buchanan brings more than 25 years of proven leadership in medical device commercialization, operations, and finance. Most recently he served as the Chief Operating Officer and Chief Financial Officer of Silk Road Medical, where he led the company from founding through its IPO in 2019, and then its $1.3 billion acquisition by Boston Scientific in 2024.

“We are thrilled to welcome Lucas to our Board of Directors at a significant time in Aerin’s growth,” said Matt Brokaw, President and CEO of Aerin Medical. “His experience and insights will be invaluable assets as we strengthen our market leadership foundation and work to change the standard of care for patients suffering from chronic ENT conditions.”

“Aerin Medical, in deep partnership with the ENT community, is improving the quality of life for individuals with nasal airway obstruction and chronic rhinitis, and I’m honored to join the company’s Board of Directors,” said Lucas Buchanan. “Throughout my career, I’ve aligned with organizations that combine standout innovation with compelling clinical evidence and meaningful patient impact, and I look forward to supporting this team’s mission-driven work.”

Mr. Buchanan also serves on the Board of Directors for Element Science, Inc., Endologix LLC, Procyrion, Inc., Route92 Medical, Inc., and as a strategic advisory board member of CRG LP, a healthcare focused investment fund. His background includes investing, finance and commercial roles at The Vertical Group, Impax Laboratories, Medtronic and Ernst & Young. He holds a BA in Economics from Duke University and an MBA in Health Care Management from The Wharton School at the University of Pennsylvania.

About Aerin Medical

Aerin Medical is a privately held, venture-backed company, headquartered in Mountain View, California. Aerin’s mission is to expand access to meaningful relief for millions of patients suffering from chronic ENT conditions. The company’s products, VivAer® for nasal airway obstruction and RhinAer® for chronic rhinitis, leverage Aerin’s proprietary temperature-controlled technology, which allows ENT physicians to reliably improve patients’ symptoms with unique technologies that are appealing alternatives to invasive surgery. More than 150,000 patients have been treated with Aerin Medical products to date. For more information, please visit www.aerinmedical.com and follow Aerin Medical on Facebook, X, Instagram, LinkedIn and YouTube.

Contacts

Media Contact:
Michael Fanucchi
Aerin Medical
mfanucchi@aerinmedical.com

Aerin Medical Inc.


Release Versions

Contacts

Media Contact:
Michael Fanucchi
Aerin Medical
mfanucchi@aerinmedical.com

More News From Aerin Medical Inc.

Aerin Medical Announces FDA Clearance and 1-Year Evidence Supporting ENT Treatment for Patients with Chronic Rhinitis and Comorbid Migraine

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aerin Medical Inc., a leader in minimally invasive solutions for chronic ENT conditions, today announced significant milestones in its groundbreaking, minimally invasive chronic rhinitis (CR) and comorbid migraine program: FDA clearance in July: RhinAer® labeling now incorporates the company’s SOOTHE study data on observed improvements in migraine-related outcomes in CR patients with comorbid migraine.1 1-year evidence: Presentations at two recent otolary...

Aerin Medical Named Preferred Vendor for Radiofrequency Technologies by US ENT Partners

MOUNTAIN VIEW, Calif. & PLANO, Texas--(BUSINESS WIRE)--Aerin Medical, the market leader in radiofrequency (RF) treatments for chronic nasal conditions, today announced a multi-year strategic partnership with US ENT Partners, the largest group purchasing organization (GPO) in otolaryngology. As part of the agreement, US ENT Partners has designated Aerin Medical as its preferred vendor for RF technology. VivAer and RhinAer are now recommended for use across the GPO's network of more than 1,500 ph...

Aerin Medical Surpasses 200,000 Patients Treated with the Company’s Minimally Invasive Solutions for Chronic Nasal Conditions

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aerin Medical Inc., a leader in minimally invasive solutions for chronic nasal conditions, today announced that more than 200,000 patients have been treated with Aerin’s RhinAer® and VivAer® temperature- and impedance-controlled radiofrequency technologies, marking a significant milestone in the adoption of these practical solutions for minimally invasive nasal procedures. This achievement reflects the growing real-world impact of RhinAer and VivAer, as a...
Back to Newsroom